Hydrothermal synthesize of HF-Free MIL-100(Fe) for isoniazid-drug delivery by Simon, Meta A et al.
1Scientific RepoRtS |         (2019) 9:16907  | https://doi.org/10.1038/s41598-019-53436-3
www.nature.com/scientificreports
Hydrothermal Synthesize of Hf-
Free MIL-100(Fe) for Isoniazid-Drug 
Delivery
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Wenny irawaty1, Truong Chi thanh3, Sandy Budi Hartono1, Maria Yuliana1 & 
Suryadi ismadji1,2*
Sustainable development of drug delivery materials with good biocompatibility and controlled-release 
is a popular topic among researchers. In this research study, we demonstrated the potential of the 
metal-organic framework, that is MIL-100(Fe), as a drug delivery platform for isoniazid (INH). The 
MIL-100(Fe) was prepared by using the hydrofluoric acid-free hydrothermal method. Several physical 
measurements were conducted to characterize the MIL-100(Fe), including x-ray diffraction (XRD), 
scanning electron microscopy (SEM), nitrogen sorption, and thermal-gravimetric (TG). The synthesized 
MIL-100(Fe) has octahedron-shaped particles with superior properties, that is large surface area 
(1456.10 m2/g) and pore volume (1.25 cm3/g). The drug loading rate and capacity were determined by 
means of adsorption kinetic and isotherm. The studied INH@MIL-100(Fe) adsorption system kinetics 
follow the pseudo-first-order model, while the isotherm system follows the Langmuir model with the 
maximum adsorption capacity of 128.5 mg/g at 30 °C. MIL-100(Fe) shows adequate biocompatibility, 
also exhibits a reasonable and controlled drug release kinetics. The results obtained show that MIL-100 
(Fe) can be a good choice of drug delivery platform among other available platforms.
Isoniazid (or isonicotinylhydrazide, abbreviated as INH) is a heterocyclic drug that contains N, which is known 
for its anti-mycobacterial properties for the treatment of Tuberculosis (TB). INH has been listed by the World 
Health Organization as an efficacious TB drug and is the first-line barrier to TB. It is known that the mechanism 
of INH in the treatment TB involves many macromolecular and biosynthesis pathways, especially the synthesis of 
mycolic acid. The practice of using INH for medicinal purposes began 60 years ago1–3. Despite its efficacy, many 
experts point out that TB treatment by using INH requires quite long time (i.e., between 6–9 months and in some 
cases can reach several years). Long-period treatment accompanied by consumption can cause hepatotoxicity 
and peripheral neuritis, as well as the emergence of drug-resistant species4–6. The long duration of TB treatment 
is due to the poor solubility and bioavailability of the INH7,8; the controlled drug delivery is one of the strategies 
to overcome these drawbacks.
A controlled and sustained drug delivery system can help to reduce the side effects and increase the efficiency 
of the treatments. Moreover, it can prevent the emergence of drug-resistance species due to fluctuations in drug 
content will cause bacteria to lack time to adapt9. Several sophisticated biomaterials have been developed to 
improve the efficiency of drug delivery systems; such as biopolymer, silica, and lipid-based materials. Despite the 
rapid development of biomaterials for drug delivery systems, the low drugs loading due to the materials small 
pore volume is still an unsatisfactory aspect10. Recently, to overcome this drawback, a large pore volume mate-
rial, namely metal-organic framework (MOF) have been utilized as drug delivery material11,12. MIL-100(Fe) is a 
MOF which composed of trimesic acid organic linker and Fe-O metal clusters. MIL-100(Fe) can be synthesized 
using organic solvent and strongly acidic solution such as HF13,14. However, HF is a chemically toxicant, and 
organic solvent such as DMF or DEF can cause environmental damage in large quantities10,15–18. Jeremias and 
co-workers revealed that the less toxic HNO3 could be used to replace HF in the synthesis of MIL-100(Fe). The 
synthesized MIL-100(Fe) has a porous structure with a large surface area (~2000 m2·g−1 BET) and pore volume 
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(~0.9 cm3·g−1)11,12,15. Due to these advantageous properties of MIL-100(Fe), it has been proposed as a potential 
drug delivery system12. Another advantage of loading drugs into highly porous materials is the prevention of drug 
agglomeration during dissolution19.
In the present study, we investigated the potential application of MIL-100(Fe) to promote the loading and 
release of INH. Several models for drug loading and release have been implemented and studied.
Materials and Methods
Materials. The chemicals used in this study are: trimesic acid (H3BTC; CAS 554-95-0), ferric chloride hex-
ahydrate (Fe(Cl)3.6H2O; CAS 7708-05-0), nitric acid 65% (HNO3; CAS 7697-37-2), isoniazid (INH, C6H7N3O; 
CAS 54-85-3), and ethanol (C2H5OH; CAS 64-17-5). Trimesic acid, ferric chloride hexahydrate, and nitric acid 
were obtained from Merck, Germany. INH, as a drug model, was obtained from Sigma Aldrich, India. Ethanol 
was purchased as an analytical grade from PT. Indofa Utama Multi-Core, Surabaya, Indonesia. All chemicals were 
directly used as received without further purification.
Preparation of MIL-100(Fe). Figure 1 shows the schematic diagram of the overall study, specifically the 
preparation of MIL-100(Fe), drug loading, and release study. MIL-100(Fe) was synthesized hydrothermally 
according to reported procedure, the molar ratio Fe:BTC:HNO3:H2O of 1: 0.67:0.6:166 was used for the syn-
thesis. Briefly, all materials were combined in a 100 mL beaker glass. Then, the mixture was loaded into a Teflon 
autoclave and heated at 150 °C for 12 h. The resulting MIL-100(Fe) solid was collected and washed for several 
times using distilled water. Subsequently, the MIL-100(Fe) solid was purified by soaking in water at 80 °C for 1 h, 
followed by ethanol at 60 °C for 3 h. The purified MIL-100(Fe) was dried in a 60 °C oven and heat-activated using 
a vacuum oven for 2 h at 120 °C.
Characterization of MIL-100(Fe). The as-synthesized MIL-100(Fe) was characterized by X-Ray 
Diffraction (XRD), Scanning Electron Microscope (SEM), Nitrogen (N2) Sorption, and Thermo-Gravimetric 
Analysis (TGA). The XRD analysis was carried out in a PW 3064/60 × ’PERT-PRO with CuKα (λ = 1.5406 Å) as 
the radiation source. The analysis was conducted at 30 mA and 40 kV. The scan range used was 3–20° (2θ) with the 
step size of 0.02°. SEM imaging was performed using FESEM-JEOL JSM-6500F to obtained crystal morphology. 
N2 sorption measurement was conducted in a Quantachorome at −195.6 °C. The surface area of the sample was 
calculated using the multiple-point Brunauer–Emmett–Teller (BET) equation at p/p0 range of 0.05–0.3 and total 
pore volume was determined at the saturated point at p/p0 = 0.997. Prior for N2 sorption measurement, MIL-
100(Fe) was outgassed at 200 °C for 6 hours. The thermal stability of MIL-100(Fe) was analyzed using Perkin 
Elmer thermogravimetric analysis (TGA) 8000 in the N2 atmosphere (20 mL/min) with heating rate 10 °C/min 
from 29.5 °C to 800 °C.
Adsorption isotherm and kinetics. The adsorption kinetics was used to determine the required time for 
INH loading onto MIL-100(Fe). Briefly, an aliquot of isoniazid (100 mg/L and 120 mg/L) was placed into a series 
of Erlenmeyer flasks. Subsequently, 0.05 g MIL-100(Fe) solid was introduced into the Erlenmeyer flasks. The 
Figure 1. Schematic diagram of the overall study, including preparation of MIL-100(Fe), drug loading and 
release.
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flasks were closed and put into a shaker water bath. The adsorption kinetic study was conducted at 30 °C. At a 
specific interval of time, one of the Erlenmeyer flasks was taken to measure the amount of INH loaded.
The adsorption isotherm was conducted according to the following procedure: A known amount of MIL-
100(Fe) was added into a series of Erlenmeyer flasks containing 25 mL of isoniazid solution. The Erlenmeyer 
flasks were transferred to a shaker water bath at 200 rpm. The adsorption was done until the equilibrium time 
was reached (in this case is 5 h, as determined from the kinetic study). The adsorption study was carried out at 
30 °C. After the equilibrium condition was achieved, the solid adsorbent was removed from the solution using 
centrifugation. The concentration of the remaining INH in the solution was measured using spectrophotometric 
measurement at 262 nm wavelength.
Drug loading and release. A certain amount of INH is dissolved in water, where the concentration of INH 
used is higher than the maximum loading capacity of MIL-100(Fe) based on adsorption study. Then, 0.05 g MIL-
100(Fe) was introduced into the INH solution in a closed-dark bottle. The loading was done by 200 rpm orbital 
shaker for 5 h under a constant temperature of 30 °C. The unloaded INH was separated by means of centrifuga-
tion, and subsequently the concentration of unloaded INH was determined using spectrophotometer (OD262nm).
In vitro release study was done to determine the release profile of INH from MIL-100(Fe). A phosphate buffer 
saline (PBS) pH 7.4 and 5.8 was used to mimic the blood plasma condition. 0.16 g of INH-loaded MOF, isonia-
zid@MIL-100(Fe), is added into a 5 mL PBS solution in a dialysis membrane. The INH release was carried out in 
80 mL PBS at 37 °C under a slow-constant stirring. At a 1 h time interval, 2 mL of solution was taken to measure 
the released-INH isoniazid by means of UV spectrophotometric; at the same time, 2 mL of fresh PBS solution was 
added into the system. The cumulative %release (R) of INH is calculated by using the following equation:
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Result and Discussion
Synthesis and characterization of MIL-100(Fe). The metal-organic framework (MOF) MIL-100 (Fe) 
is synthesized from the coordinated iron (Fe) trimers and trimesate ligands. The MIL-100(Fe) has a super tetra-
hedron structure, as depicted in Fig. 2. The coordination of diamond-like shapes MIL-100(Fe) particles produces 
small pore opening, in each cell unit20. Upon activation, the pore size can reach 29 Å and 24 Å for each large and 
small pore, respectively14,21. For comparison purposes, the synthesized MIL-100(Fe), from this study, was charac-
terized using XRD, SEM, N2 sorption, and TGA.
The XRD crystallinity pattern of synthesized MIL-100(Fe) from this study and from literature is shown in 
Fig. 3; it is observed that both XRD patterns are in a good agreement18. The 2θ peaks and the corresponding 
lattice of MIL-100(Fe), from this study, are observed at 3.4° (220), 4.0° (311), 4.8° (400), 5.3° (331), 5.9° (422), 
and 6.3° (333). Calculations by using Miller indexing and Bragg’s law indicate that the synthesized MIL-100(Fe) 
has a cubic structure with a lattice parameter of 73 Å; which is in accordance with a previous report21,22. The 
SEM micrographs were collected to confirm the morphology of MIL-100(Fe). As shown in Fig. 4, MIL-100(Fe) 
has an octahedron shape which belongs to the cubic (isometric) crystal; this is in accordance with the structure 
suggested from XRD. Also, from the SEM images, some small irregular-shaped particles can be observed, which 
is probably the MIL-100(Fe) whose structure collapsed.
Enormous surface and large pore volume are distinguishing properties of MOFs; these two properties are 
measured by using N2 adsorption-desorption isotherm for the synthesized MIL-100(Fe). The N2-sorption iso-
therm curve is shown in Fig. 5. As derived from the sorption data, the BET surface area and pore volume of MIL-
100(Fe) are 1456.10 m2/g and 1.25 cm3/g, respectively; this result is quite similar to that of reported MIL-100(Fe) 
in Table 1. The N2-sorption curve of MIL-100(Fe) indicates a combination of type I and IV with a narrow hystere-
sis loop in the relative pressure (P/Po) range of 0.6 to 1.0. The rapid intake of N2 gas at relatively low P/Po indicates 
that MIL-100(Fe) possesses both microporous and mesoporous cages23,24. The reported drug delivery materials 
(i.e., MSN8, MSN5, beta zeolites, and MCM-41) are shown in Table 1; it is well noted that the MIL-100(Fe) pos-
sesses higher surface area and pore volume, which is more favorable to facilitate drug loading.
The thermal stability of MIL-100(Fe) was investigated by using thermogravimetric analysis; the resulting TG 
curve is shown in Fig. 6. The MIL-100(Fe) exhibits 3 stages weight loss; that is at temperature range of 60–340 °C 
with 5% weight loss, at 340–400 °C with 34.20% weight loss, and at 400–680 °C with 38.90% weight loss. The first 
stage thermal degradation is corresponding to the removal of trapped water molecules followed by mild decom-
position of O-containing functional groups. A minimal weight loss (almost plateau) at the first stage also indi-
cates that the MIL-100(Fe) is stable up to this range of temperature. Substantial weight loss was observed above 
temperature of 340 °C; this is due to the structural collapse of the MIL-100(Fe) as the ligand was decomposed. 
The subsequent drastic mass reduction started at 400 °C, which is caused by the continuous decomposition of the 
framework accompanied by the reduction of the iron25,26. The third stage degradation ends up to 680 °C, which 
also indicates that MIL-100(Fe) is completely decomposed.
Adsorption kinetic. The adsorption rate of INH, with MIL-100(Fe) as host adsorbate, was studied kineti-
cally to find the equilibrium adsorption time. The adsorption kinetics was represented by the pseudo-first-order 
(Eq. 3) and the pseudo-second-order equations (Eq. 4), which has the mathematical forms as following27:
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Figure 2. Illustrated crystal structure of MIL-100(Fe).
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Figure 3. X-ray diffraction pattern of MIL-100(Fe).
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where, qe and qt (mg/g) are the amount of INH adsorbed on MIL-100(Fe) at equilibrium and at time t (hours), 
respectively. The k1 and k2 are the pseudo-first-order and pseudo-second-order adsorption constant, respectively. 
Often, k1 and k2 called as time constant.
The adsorption kinetic curve built from the experimental data was presented in Fig. 7, while the calculated 
parameters are summarized in Table 2. The experimental data show that the adsorption equilibrium time was 
reached after 5 h. The pseudo-first-order and pseudo-second-order model equation were used for data fitting.
The curve fitting shows that the pseudo-first-order model can correlate the calculated and experimen-
tal data better than that of pseudo-second-order. Moreover, the qt value found from pseudo-first-order fit-
ting was closer to that of experimental results. The sum square error (SSE) of the data was also calculated; it 
Figure 4. SEM image of the synthesized MIL-100(Fe).
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Figure 5. Nitrogen adsorption-desorption isotherm of MIL-100(Fe).
Material
BET surface 
area (m2/g)
Pore volume 
(cm3/g) Ref.
MSN8 715 1.697 37
MSN5 650 1.229 37
Beta zeolites 513 0.23 38
MCM-41 1506 Not available 39
MIL-100(Fe) 1190–1520 0.69–0.93 40
MIL-100(Fe) 1835 1.23 41
MIL-100(Fe) 1456.10 1.25 This study
Table 1. Comparison of BET surface area and pore volume of MIL-100(Fe) with other porous materials. 
MSN8 = mesoporous silica nanoparticles with pore size 8.2 nm; MSN5 = mesoporous silica nanoparticles with 
pore size 5.4 nm; Beta zeolites = Al2O3:2 SiO2:TEA2O:30 H2O; MCM-41 = mobil composition of matter no. 41, a 
mesoporous silica material.
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is obtained that the SSE of pseudo-first-order and pseudo-second-order successively is 4.089 and 6.188. The 
values of R2 for pseudo-first-order are 0.994 for 100 mg/L and 0.998 for 120 mg/L, which is higher than R2 from 
pseudo-second-order (0.970 for 100 mg/L and 0.994 for 120 mg/L). The error analysis also indicates that the 
pseudo-first-order model could represent the experimental data better than the pseudo-second-order equation.
The value of k1 > k2 suggests that intra-particle diffusion (IPD) is the rate-limiting in the adsorption of INH 
onto MIL-100(Fe)28. The adsorption rate decreases as the INH concentration is increased, this may be due to the 
higher probability of collision (at high concentration) so that the IPD is inhibited.
Adsorption isotherm. Adsorption isotherm study was conducted to determine the loading capacity MIL-
100 (Fe) against INH. The adsorption isotherm is represented by the Langmuir and Freundlich models, with 
mathematical models as following29:
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Figure 6. The thermogravimetric curve of MIL-100(Fe).
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Figure 7. Adsorption kinetics curves of INH@MIL-100(Fe) system.
Model Parameters
Initial concentration, mg/L
100 120
Pseudo 1st order
k1, g/mg·h 1.040 ± 0.095 0.719 ± 0.044
qe, mg/g 92.681 ± 2.678 110.271 ± 2.257
R2 0.994 0.998
Pseudo 2nd order
k2, g/mg·h 0.010 ± 0.249 0.005 ± 0.091
qe, mg/g 110.631 ± 20.688 138.898 ± 8.864
R2 0.970 0.994
Table 2. Adsorption kinetics of INH@MIL-100(Fe).
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where, KL and qm are the Langmuir constant and maximum adsorption capacity (mg/g), respectively. KF ((mg/g) 
(L/mg)1/n) and n are the Freundlich constants.
The adsorption isotherm curve of INH@MIL-100 (Fe) system is shown in Fig. 8. A steep increase from qe was 
observed to Ce ± 50 mg/g; almost a plateau was observed later which indicated that the maximum adsorption 
capacity almost reached. The fitting parameters of the Freundlich and Langmuir models are given in Table 3, 
from R2 value it was evident that Langmuir could represent the experimental data better than the Freundlich. The 
superiority of Langmuir over Freundlich equation due to the system has saturation capacity at high Ce. Based on 
the isotherm measurement, approximately 128 mg of INH can be loaded onto MIL-100(Fe).
Drug kinetic release. The in vitro drug release is conducted to study the INH release. A PBS solution was 
used as the release medium to simulate the biological condition. Two different release pH of 5.8 and 7.4 were con-
sidered to mimic the intestine pH and blood pH, respectively30. The total INH content was determined by gently 
stirring the INH@MIL-100(Fe) in PBS for 24 h, then the concentration of INH released into the PBS solution was 
determined by using UV spectroscopy method. The release profile data of INH@MIL-100(Fe) are shown in Fig. 9. 
There is no burst effect occurred during the INH release in PBS solution at both pHs; this indicates that MIL-
100(Fe) can be a potential biocompatible drug release platform.
The kinetic release was represented as the % cumulative release (R). Then, R was fitted to zero-order (Eq. 7)31, 
first-order (Eq. 8)23, and Higuchi (Eq. 9)31 model:
= +R q k t (7)0 0
= − −R R e(1 ) (8)e
kt
= .R k t (9)H
0 5
where, k0, k, and kH are the kinetic constant of zero-order (mg/g·h), first-order (1/h), and Higuchi (%/h0.5) model, 
respectively. The parameter Re, q0, and t represent the % release of INH at equilibrium time, initial amount of INH 
in PBS (mg/g), and release time (h), respectively. Later on, a good fitting to the zero-order model indicates that the 
release system is a transdermal and osmotic system. A good fitting to the first-order model describes the release 
system of water-soluble drugs in a non-swelling porous matrix32. While a good fitting to Higuchi model indicates 
drug release from a planar heterogeneous matrix system by passing through the pore matrix33.
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Figure 8. Adsorption isotherm curve of INH@MIL-100(Fe) system.
Model Parameter Value
Langmuir
KL, L/mg 0.056 ± 0.006
qm, mg/g 128.518 ± 0.687
R2 0.996
Freundlich
KF, (mg/g)(L/mg)1/n 40.776 ± 5.061
n 0.207 ± 0.027
R2 0.989
Table 3. Adsorption isotherm of INH@MIL-100(Fe).
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The model fitting into the release profile data of INH@MIL-100(Fe) is shown in Fig. 9, and the fitted param-
eters are summarized in Table 4. The error analysis of SSE and R2 show that the release profile of INH@MIL-
100(Fe) is better represented by the first-order model, which typical for a drug release system from porous 
matrices. This suggests that the release mechanism is a continuous-controlled release system with different release 
rates9. Moreover, from experimental data, the R-value for release system at pH 5.8 and pH 7.4 (after 24 h) is found 
to be 50.38% and 72.22%, respectively. Meanwhile, the Re (and k) value calculated from the first-order model is 
found to be 53.037% (0.120/h) and 72.289% (0.122/h), for pH 5.8 and 7.4, respectively. Both experimental and 
calculated result shows a good agreement. The release of INH is better in alkaline pH because in this condition 
there are more negatively charged molecules (from water) that can bind to the metal cluster of MIL-100(Fe), this 
will cause interference for interactions between the INH molecules and MIL-100(Fe) active surface.
Some release profile of MIL-100(Fe) and modified MIL-100(Fe) against several drugs are presented in Table 5. 
Based on the collected data, there is still no release data reported for INH@MIL-100(Fe) system. In comparison 
with other drug release study, it can be seen that the MIL-100(Fe) prepared in this study can match almost all 
reported release data.
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Figure 9. The drug release profile of INH@MIL-100(Fe) system, at pH 5.8 and pH 7.4.
Figure 10. Cell viability assay of MIL-100(Fe) at different concentrations and certain incubation period.
Model Parameters pH 5.8 pH 7.4
Higuchi
kH, %/h0.5 10.748 ± 0.829 14.356 ± 1.339
R2 0.978 0.970
Zero Order
k0, mg/g·h 1.834 ± 0.188 2.472 ± 0.271
Re, mg/g 12.020 ± 2.415 15.969 ± 3.442
R2 0.8732 0.865
First Order
Re, % 53.037 ± 0.734 72.289 ± 1.345
k, 1/h 0.120 ± 0.004 0.122 ± 0.005
R2 0.997 0.995
Table 4. Release kinetic of INH@MIL-100(Fe).
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Biocompatibility assay. Safe drug delivery materials must have little or no toxic effect on normal cells. In this 
study, an MTT assay on mouse osteoblast cells 7F2 was used to test the biocompatibility of the drug delivery material, 
that is MIL-100(Fe). MIL-100(Fe) at particular concentration (25, 50, or 100 μg/mL) was introduced to the cell culture 
and incubated for periods of 12, 24, and 48 h (Fig. 10). The detail of the procedure can be seen elsewhere34. Relatively 
high cell viability (up to 83%, after 24 h incubation; and ~79%, after 36 h incubation) was maintained by using 25 μg/
mL of MIL-100(Fe) which shows biocompatibility of this material, at this concentration35. It was observed that cell 
viability was decreased significantly at higher MIL-100(Fe) concentrations, also the prolonged incubation times lead-
ing to cell toxicity. This indicates that MIL-100(Fe) should not be administered at concentrations of more than 25 μg/
mL due to its cytotoxic effect (Fig. 10). Cytotoxicity of MIL-100(Fe) may be caused by the presence of Fe metal which 
triggers the generation of reactive oxygen species that can cause cell damage36. In addition, the presence of metals 
(in metal-organic materials) increases the ability to penetrate into the cells thus induce more severe tissue damage.
Conclusion
The metal-organic framework, namely MIL-100(Fe), has been successfully synthesized using the hydrothermal 
method. The as-synthesized MIL-100(Fe) has a cubic crystal structure with a large surface area and pore volume 
which can facilitate drug loading. The characteristics of the synthesized MIL-100(Fe) is in good agreements with 
the reported characteristics. The adsorption study of INH onto MIL-100(Fe) indicates that intra-particle diffusion 
was the rate-limiting in the system. The maximum uptake of INH@IL-100(Fe) is found to be 128.5 mg/g based on 
Langmuir model; which represents the approximate drug loading capacity of MIL-100(Fe). Based on the release 
profile, MIL-100(Fe) show a good controlled-release of INH and there is no burst observed during the release. 
Furthermore, the MIL-100(Fe) itself show a good biocompatibility. All of these findings imply that MIL-100(Fe) 
is a promising drug delivery platform for INH.
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